Zentalis Pharmaceuticals, Inc.
ZNTL
$3.87
-$0.16-3.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.61% | -0.39% | -31.94% | 0.68% | 44.34% |
| Total Depreciation and Amortization | 1.32% | -3.82% | -1.88% | 0.00% | -38.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.49% | -45.92% | 644.85% | 120.96% | -97.55% |
| Change in Net Operating Assets | 337.77% | 47.17% | -17.78% | 85.95% | -574.80% |
| Cash from Operations | -12.99% | -6.52% | -14.75% | 22.31% | -6.35% |
| Capital Expenditure | 100.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | 11,180.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -0.08% | -7.03% | 14.12% | -5.01% | -26.33% |
| Cash from Investing | 0.03% | -7.50% | 14.58% | -6.77% | -24.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -80.36% | -93.86% | 4,586.96% | -- | -100.00% |
| Repurchase of Common Stock | 100.00% | 85.43% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 105.79% | 75.51% | -4,087.83% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.82% | -32.11% | -308.89% | 134.02% | -153.94% |